Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Mark Capriani, MBA

President and Chief Executive Officer
AciesHealth
Member of the Healthcare Council

Mark Capriani, MBA, is the President and Chief Executive Officer of AciesHealth, a specialty pharmaceutical company in Pennsylvania. He has over 15 years of experience in pharmaceutical industry including biotech, branded and multi source pharmaceuticals, consumer products, device, and wound and burn care products. Mr. Capriani is an expert in the areas of cardiovascular, dermatology, diabetes, neurology, and pain management. He is also experienced in business development, managed care, marketing, and sales. Mr. Capriani has served as the President and Chief Executive Officer of Helix Pharmaceuticals, Inc. Prior to Helix, he has held various positions at Alpharma, Bertek, Elan, and Mylan Laboratories. (This is me - Update Profile)


Employment History
2005 - present President and Chief Executive Officer
AciesHealth
2002 - 2005 President and Chief Executive Officer
Helix Pharmaceuticals
2000 - 2002 Director
Elan Pharmaceuticals

GLG Study Groups with Mark Capriani, MBA(?)

View All Study Groups with Mark Capriani, MBA

GLG NewsSM Analyses by Mark Capriani, MBA(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Recent Trends Give Xyzal Blockbuster Potential | 05-30-2007
Analysis of: FDA Approves XYZAL(R) (Levocetirizine Dihydrochloride) Tablets For The Relief Of Seasonal And Year Round Allergies, And Chronic Hives | www.medicalnewstoday.com
Author: Mark Capriani, MBA, President and Chief Executive Officer, AciesHealth

FDA approval for UCB / Sanofi-Aventis new prescription drug Xyzal for treatment of seasonal and perennial comes at the perfect time for a big win for the pharmaceutical companies.  Xyzal has the potential to be the next blockbuster. The key questions:  Will physicians embrace the new med;...

GLG InstituteSM Seminars with Mark Capriani, MBA(?)

 
Mark Capriani, MBA has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Mark Capriani, MBA









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics